Exclusive Marketing Authorization and Intellectual Property Protection

1. Key takeaways

Article 4 allows EDE to grant exclusive marketing authorizations, and Article 6(1)(e) requires the applicant to demonstrate compliance with respect to intellectual property and trademarks. Our judgment is that these two provisions are often conflated but in fact point at different things: Article 4 deals with who may enter the market as the rights holder, while Article 6(e) deals with whether the product itself carries defects in rights. For a Chinese manufacturer applying for an exclusive authorization, the real preparatory work lies not in the application form itself but in demonstrating lawful rights to the trademark, the patents and the technical documentation, together with the absence of any improper use of another party’s data.

• Article 4 allows EDE to grant exclusive marketing authorizations; exclusivity concerns the uniqueness of the rights holder for the same product.
• Article 6(1)(e) requires the applicant to demonstrate intellectual property and trademark compliance, which in practice means a verifiable chain of rights.
• Exclusivity of rights and the multiple-agent structure are not in conflict: Article 22 still requires at least 2 importers, at least 1 distributor and 1 lead responsible entity, each actually importing in the year concerned.
• For generic-type products, the risk concentrates in the lawful basis for using originator data, under Article 6(2).

2. Legal basis

The exclusive authorization and the intellectual property conditions rest on Article 4 and Article 6 of Federal Decree-Law No. 38/2024, together with the distribution-side structure of Article 22, summarised below.

3. Expert insights

Insight 1: The exclusive marketing authorization and Article 22 do not conflict, and this is the pairing most often misread. The exclusivity of Article 4 limits the uniqueness of the rights holder, meaning that only one marketing rights holder exists for the same product. Article 22 limits the distribution side, requiring that rights holder to appoint at least 2 importers and at least 1 distributor. On 24 February 2026, EDE activated the monopoly-breaking mechanism under Federal Decree-Law No. 38/2024, requiring more than 1 authorised agent to be appointed for every medical product placed on the UAE market. Our judgment is that exclusive rights and a multiple-agent structure can coexist; what a Chinese manufacturer needs to rebuild is the agency contracts and the supply chain arrangements, not the exclusive status itself.

Insight 2: Item (e) examines the chain of rights, not a single trademark certificate. The requirement to demonstrate intellectual property and trademark compliance translates, at the operational level, into assembling the trademark ownership, the patent status, the provenance of the technical documentation and the chain of authorisations into one verifiable record. We have encountered cases where the rights holder and the trademark holder were different parties, and cases where the technical documentation came from a third party with no authorisation document in place. Problems of this kind are difficult to resolve through supplementary explanations during review and should be cleaned up before the filing.

Insight 3: For generic-type products the risk concentrates in the use of data. Article 6(2) prescribes separate conditions for generic products, and read together with item (e), a generic manufacturer citing originator clinical data or technical information must have a lawful basis for doing so. Our position is that it is better to spend more time before filing on rights due diligence and the assembly of authorisation documents than to be drawn into a dispute after approval. Article 19 on the handling of academic misconduct and Article 17 on revocation both point to a long-term responsibility for the truthfulness and compliance of data.

4. Practical recommendations

• Complete rights due diligence before applying for the exclusive authorization: the ownership of trademarks, patents and technical documentation, and the chain of authorisations, recorded in writing.
• Where the rights holder and the trademark holder are different parties, arrange a transfer or issue a clear authorisation document in advance and explain it in the filing material.
• Check the conditions for generic products separately under Article 6(2), and ensure any citation of originator data rests on a lawful basis with vouchers retained.
• Rebuild the agency contracts on the multiple-agent structure, defining the rights and duties of each importer, distributor and the lead responsible entity, to avoid Article 22 implementation obstacles.
• Include protective terms on certificate ownership in the contracts, so that an agent cannot claim vested rights after the cooperation ends.
• Obtain written confirmation from EDE on the application conditions for the exclusive authorization and the required corroborating materials, and do not substitute practice for matters the Executive Regulations leave open.

5. Verification checklist

• □ It is clear that the application is for an exclusive marketing authorization, with the Article 4 basis explained in the application.
• □ The ownership of trademarks, patents and technical documentation and the chain of authorisations are recorded in a verifiable written form.
• □ Any discrepancy between the rights holder and the trademark holder has been resolved through a transfer or an authorisation document.
• □ Generic products have been checked against Article 6(2), and every data citation rests on a lawful basis.
• □ The importer, distributor and lead responsible entity arrangements of Article 22 are written into the contracts, with the annual actual-import requirement stated.
• □ A written reply from EDE has been obtained on the list of corroborating materials for the exclusive authorization.

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages MOHAP registration applications, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com